Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 20;64(9):e01003-20.
doi: 10.1128/AAC.01003-20. Print 2020 Aug 20.

How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide

Claudio U Köser  1 , Daniela M Cirillo  2 , Paolo Miotto  3
Affiliations

How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide

Claudio U Köser et al. Antimicrob Agents Chemother. .

Abstract

False-susceptible phenotypic drug-susceptibility testing (DST) results for pyrazinamide due to mutations with MICs close to the critical concentration (CC) confound the classification of pncA resistance mutations, leading to an underestimate of the specificity of genotypic DST. This could be minimized by basing treatment decisions on well-understood mutations and by adopting an area of technical uncertainty for phenotypic DST rather than only testing the CC, as is current practice for the Mycobacterium tuberculosis complex.

Keywords: genotypic DST; pncA; pyrazinamide.

PubMed Disclaimer

References

    1. Lamont EA, Dillon NA, Baughn AD. 2020. The bewildering antitubercular action of pyrazinamide. Microbiol Mol Biol Rev 84:e00070-19. doi:10.1128/MMBR.00070-19. - DOI - PMC - PubMed
    1. World Health Organization. 2018. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. World Health Organization, Geneva, Switzerland: http://apps.who.int/iris/bitstream/handle/10665/275469/9789241514842-eng....
    1. Morlock GP, Tyrrell FC, Baynham D, Escuyer VE, Green N, Kim Y, Longley-Olson PA, Parrish N, Pennington C, Tan D, Austin B, Posey JE. 2017. Using reduced inoculum densities of Mycobacterium tuberculosis in MGIT pyrazinamide susceptibility testing to prevent false-resistant results and improve accuracy: a multicenter evaluation. Tuberc Res Treat 2017:3748163. doi:10.1155/2017/3748163. - DOI - PMC - PubMed
    1. El Achkar S, Demanche C, Osman M, Rafei R, Ismail MB, Yaacoub H, Pincon C, Duthoy S, De Matos F, Gaudin C, Trovato A, Cirillo DM, Hamze M, Supply P. 2019. Drug-resistant tuberculosis, Lebanon, 2016–2017. Emerg Infect Dis 25:564–568. doi:10.3201/eid2503.181375. - DOI - PMC - PubMed
    1. Fofana MO, Dowdy DW. 2017. Reply to Anthony et al., “Protecting pyrazinamide, a priority for improving outcomes in multidrug-resistant tuberculosis treatment”. Antimicrob Agents Chemother 61:e00427-17. doi:10.1128/AAC.00427-17. - DOI - PMC - PubMed

Publication types

MeSH terms